Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 1398-1399, 2008; 10.1373/clinchem.2008.109850
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dahl, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Dahl, M.
Related Collections
Right arrow Clinical Case Studies
(Clinical Chemistry. 2008;54:1398-1399.)
© 2008 American Association for Clinical Chemistry, Inc.

Clinical Case Study

Commentary

Morten Dahl

Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University, Denmark.

Address correspondence to this author at: Department of Clinical Biochemistry, Herlev Hospital, DK-2730 Herlev, Denmark. E-mail mordah02@heh.regionh.dk.

The first 20% of the full text of this article appears below.

It is estimated that there are at least 100 000 individuals with {alpha}1-antitrypsin (A1AT) deficiency in the US, but only 6000 of these had been identified by 2006 (1). If the diagnosis rate increases in the future, prevention could become a promising alternative to treatment of the disease. Guidelines from the American Thoracic Society and European Respiratory Society . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.